Close
ACHEMA MIDDLE EAST 2026

2028 May See European Pharma Firms Cross US Giants In Sales

The worldwide pharmaceutical sector is going through a major overhaul that is most definitely going to shape its future. It is estimated that by...

Buyouts Dwindle As Pharma Sector Faces Pricing Concerns

The pharmaceutical industry is currently facing various challenges, including concerns about pricing due to the Inflation Reduction Act and increased scrutiny from the Federal...

Unconstitutional Price-Setting Provisions: PhRMA Asserts

NICA, PhRMA, and GCCA lodged a complaint in the U.S. District Court for the Western District of Texas, asserting that the price setting provisions...

Pharma May Lose Out To Competition Due To EU Health Package

In a major concern surrounding Europe’s pharma industry, there is an anticipation that it could go on to lose out to elevated competition from...

Pharma Trade Group Sues Biden Admin Over Medicare Drug Costs

On June 21, the pharma sector’s biggest lobbying group, along with two major organisations, went on to sue the Biden administration when it came...

Cell & Gene Therapy CDMO Market – Steady Growth On The Cards

The cell and gene therapy CDMO services market happened to be valued at $5193.7 million last year and is now anticipated to grow at...

Cell And Gene Therapy CDMO Services Set For Rapid Growth

The global cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services market, which was valued at USD 5,193.7 million in 2022, is...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...